Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L

Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L

Abstract Antiangiogenic treatment targeting the vascular endothelial growth factor (VEGF) pathway is a powerful tool to combat tumor growth and progression; however, drug resistance frequently emerges. We identify CD5L (CD5 antigen-like precursor) as an important gene upregulated in response to anti...

Full description

Bibliographic Details
Main Authors: Christopher J. LaFargue, Paola Amero, Kyunghee Noh, Lingegowda S. Mangala, Yunfei Wen, Emine Bayraktar, Sujanitha Umamaheswaran, Elaine Stur, Santosh K. Dasari, Cristina Ivan, Sunila Pradeep, Wonbeak Yoo, Chunhua Lu, Nicholas B. Jennings, Vinod Vathipadiekal, Wei Hu, Anca Chelariu-Raicu, Zhiqiang Ku, Hui Deng, Wei Xiong, Hyun-Jin Choi, Min Hu, Takae Kiyama, Chai-An Mao, Rouba Ali-Fehmi, Michael J. Birrer, Jinsong Liu, Ningyan Zhang, Gabriel Lopez-Berestein, Vittorio de Franciscis, Zhiqiang An, Anil K. Sood
Format: Article
Language:English
Published: Nature Portfolio 2023-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-36910-5

Internet

https://doi.org/10.1038/s41467-023-36910-5

Similar Items